Compare VRTS & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VRTS | SPRY |
|---|---|---|
| Founded | 1988 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 968.0M | 796.4M |
| IPO Year | 1995 | 2020 |
| Metric | VRTS | SPRY |
|---|---|---|
| Price | $151.57 | $8.56 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $158.00 | $40.00 |
| AVG Volume (30 Days) | 87.0K | ★ 1.8M |
| Earning Date | 05-01-2026 | 05-11-2026 |
| Dividend Yield | ★ 6.68% | N/A |
| EPS Growth | ★ 18.24 | N/A |
| EPS | ★ 1.05 | N/A |
| Revenue | N/A | ★ $84,278,000.00 |
| Revenue This Year | N/A | $87.40 |
| Revenue Next Year | $1.66 | $81.64 |
| P/E Ratio | $144.35 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $121.61 | $6.66 |
| 52 Week High | $214.88 | $18.63 |
| Indicator | VRTS | SPRY |
|---|---|---|
| Relative Strength Index (RSI) | 61.04 | 46.48 |
| Support Level | $135.84 | $8.50 |
| Resistance Level | $169.44 | $8.61 |
| Average True Range (ATR) | 5.98 | 0.58 |
| MACD | 0.65 | -0.21 |
| Stochastic Oscillator | 99.02 | 31.45 |
Virtus Investment Partners Inc provides investment management and related services to institutions and individuals. It uses a multi-manager, multi-style approach, offering investment strategies from investment managers, each having its distinct investment style, autonomous investment process, and individual brand, as well as from select unaffiliated managers for certain funds. Through its multi-manager model, the group provides investment managers with distribution, business, and operational support. The Company operates in one business segment, namely as an asset manager providing investment management and related services for individual and institutional clients.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.